≡ Risteys
R13

Documentation Changelog GitHub Contact & Feedback
info icon

Malignant neoplasm of uterus, part unspecified, including Hilmo

Endpoint Browser

C3_UTERUS_NAS_WIDE

Endpoint definition

↥

Report an error or suggest an improvement for this endpoint codes

Endpoint definition steps

FinnGen

Phenotype data

519972

1. Apply sex-specific rule

only females

293218

2. Check conditions

None

293218

3. Check pre-conditions, main-only, mode, registry filters

Registry filters:

  • Hospital discharge: ICD-10 — C55
  • Hospital discharge: ICD-8 — 182
  • Cause of death: ICD-10 — C55
  • Cause of death: ICD-8 — 182
  • Cause of death: excluded ICD-8 — 1820
  • Cancer registry: Topography ICD-O-3 — C55
  • Cancer registry: Morphology ICD-O-3 — ANY
  • Cancer registry: Behaviour codes — 3

3 out of 7 registries used, show all original rules.

179

4. Check minimum number of events

None

179

5. Include endpoints

None

179

6. Filter based on genotype QC (FinnGen only)

173

Control definitions (FinnGen only)

Control exclude
C3_CANCER, C3_CANCER_WIDE

Extra metadata

First used in FinnGen datafreeze
DF12

Case counts by codes

↥

FinnGen case counts by registry codes:

generic upset plot

Upset plot

Full data table

Summary Statistics

↥

-FinRegistry-

This endpoint is excluded (different definition than used in FinnGen).

-FinnGen-

Key figures

All Female Male
Number of individuals 173 173 -
Unadjusted period prevalence (%) 0.06 0.06 -
Median age at first event (years) 55.72 55.72 -

-FinnGen-

Age distribution of first events

-FinnGen-

Year distribution of first events

-FinnGen-

Cumulative Incidence Function

Not a core endpoint, no data to show.

CodeWAS

↥

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.

Matched cohort

Matched cases
179
Matched controls
1790
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
128
Kela drug reimbursment
Cancers of female genital organs
+∞
102.1
88
*
C55
ICD-10 Finland
Malignant neoplasm of uterus, part unspecified
+∞
81.7
72
*
8380/3-C54.9
ICD-O-3
Endometrioid adenocarcinoma, NOS, of corpus uteri
+∞
74.2
66
*
18200
ICD-8 Finland
Other malignant neoplasm of uterus, Carcinoma corporis uteri
+∞
64.6
58
*
C54.11
ICD-10 Finland
Adenocarcinoma of the endometrium
+∞
48.1
44
*
LAF11
NOMESCO Finland
Laparoscopic bilateral salpingo-oophorectomy
12.3
28.8
31
30
8380/3-C54.1
ICD-O-3
Endometrioid adenocarcinoma, NOS, of endometrium
+∞
22.4
21
*
115
Kela drug reimbursment
Breast cancer
+∞
19.1
18
*
ZX012
NOMESCO Finland
Radiotherapy with large shaped fields - isocentric therapy
211.2
18.9
19
*
H02AB02
ATC
dexamethasone; systemic
28.8
18.8
25
10
18220, ,
ICD-8 Finland
+∞
15.9
15
*
PJA12
NOMESCO Finland
Sentinel node biopsy
174.6
15.7
16
*
130
Kela drug reimbursment
Malignant tumour
+∞
14.8
14
*
A03FA01
ATC
metoclopramide; systemic, rectal
3.9
14.1
52
170
LCD01
NOMESCO Finland
Total laparoscopic hysterectomy
37.3
13.8
17
5
C54.9
ICD-10 Finland
Malignant neoplasm: Corpus uteri, unspecified
+∞
13.7
13
*
8500/3-C50.9
ICD-O-3
Infiltrating duct carcinoma, NOS, of breast, NOS
+∞
13.7
13
*
WF003
NOMESCO Finland
Adjuvant radiotherapy
+∞
13.7
13
*
PJD64
NOMESCO Finland
Laparoscopic dissection of iliac lymph nodes
+∞
13.7
13
*
WB113
NOMESCO Finland
Multiple adjuvant cytostatic therapy
+∞
13.7
13
*
JN4BD
NOMESCO Finland
Extensive body CT
6.5
13.1
23
40
XLD00
NOMESCO Finland
Sytologyspecimen from mouth of uterus
4.3
12.9
39
110
L03AA13
ATC
pegfilgrastim; parenteral
+∞
12.6
12
*
WF049
NOMESCO Finland
Radiotherapy of metastasis
+∞
12.6
12
*
C44.31
ICD-10 Finland
Basocellular carcinoma of the skin on another or unspecified part of the face
139.4
12.6
13
*
L02BG04
ATC
letrozole; oral
139.4
12.6
13
*
B01AB10
ATC
tinzaparin; parenteral
4.7
11.9
30
73
18221, ,
ICD-8 Finland
+∞
11.6
11
*
C50.41
ICD-10 Finland
Malignant tumor of the upper outer quadrant of the mammary gland, ductal tumor
+∞
11.6
11
*
PJD52
NOMESCO Finland
Block dissection of axillary lymph nodes
+∞
11.6
11
*
A04AA02
ATC
granisetron; systemic, transdermal
127.9
11.6
12
*
LX1XE
NOMESCO Finland
Other gynecological ultrasound examination
10.7
11.1
21
22
WD105
NOMESCO Finland
Cystostatic therapy of methastized malignancy
116.6
10.5
11
*
L02BA01
ATC
tamoxifen; oral
+∞
10.5
10
*
HAB40
NOMESCO Finland
Wedge excision of mammary gland
+∞
10.5
10
*
C79.8
ICD-10 Finland
Secondary malignant neoplasm of other specified sites
+∞
10.5
10
*
C50.99
ICD-10 Finland
Breast, unspecified
+∞
10.5
10
*
8890/3-C55.9
ICD-O-3
Leiomyosarcoma, NOS, of uterus, NOS
+∞
10.5
10
*
A04AA01
ATC
ondansetron; systemic, rectal
9.2
9.9
20
24
HA1AA
NOMESCO Finland
X-ray mammography
8.3
9.7
21
28
8090/3-C44.9
ICD-O-3
Basal cell carcinoma, NOS, of skin, NOS
+∞
9.5
9
*
C54.1
ICD-10 Finland
Malignant neoplasm: Endometrium
+∞
8.4
8
*
N02AB03
ATC
fentanyl; nasal, sublingual, transdermal
4.6
7.7
19
45
WZC00
NOMESCO Finland
Treatment plan or consultation
2.6
7.6
54
251
ZX090
NOMESCO Finland
Other technic of radiotherapy
83.4
7.5
8
*
18201
ICD-8 Finland
Other malignant neoplasm of uterus, Carcinoma corporis et cervicis uteri
+∞
7.3
7
*
YJ2VG
NOMESCO Finland
MRI examination of pelvis with high intensity magnet for dose design of radiotherapy
+∞
7.3
7
*
YL1AD
NOMESCO Finland
CT examination of pelvis for dose design of radiotherapy
+∞
7.3
7
*
18202
ICD-8 Finland
Other malignant neoplasm of uterus, Sarcoma uteri
+∞
7.3
7
*
L01BC06
ATC
capecitabine; oral
+∞
7.3
7
*
1820A
ICD-9 Finland
Malignant neoplasm of body of uterus, Corpus uteri, except isthmus[CARCINOMA ENDOMETRII]
+∞
7.3
7
*
YG1BD
NOMESCO Finland
Extensive CT examination of thorax for dose design of radiotherapy
+∞
7.3
7
*
WB103
NOMESCO Finland
Simple adjuvant cytostatic therapy
+∞
7.3
7
*
JN2CG
NOMESCO Finland
Extensive MRI examination of lower part of abdoment with high intensity magnet
+∞
7.3
7
*
HAC20
NOMESCO Finland
Total mastectomy
+∞
7.3
7
*
PJD54
NOMESCO Finland
Block dissection of iliac lymph nodes
+∞
7.3
7
*
XX3DW
NOMESCO Finland
Time consuming IT work
4.6
6.9
17
40
N95.0
ICD-10 Finland
Postmenopausal bleeding
2.9
6.5
35
140
HA1AE
NOMESCO Finland
Ultrasound examination of mammary glands
8.7
6.5
13
16
8070/3-C53.9
ICD-O-3
Squamous cell carcinoma, NOS, of cervix uteri
+∞
6.3
6
*
C50.90
ICD-10 Finland
Malignant tumor in other or unspecified location in mammary gland without histology
+∞
6.3
6
*
8140/3-C20.9
ICD-O-3
Adenocarcinoma, NOS, of rectum, NOS
+∞
6.3
6
*
WD125
NOMESCO Finland
Demanding cystostatic therapy of methastized malignancy
+∞
6.3
6
*
18301
ICD-8 Finland
Malignant neoplasm of ovary, Fallopian tube and broad ligament, Ovary
+∞
6.3
6
*
8090/3-C44.3
ICD-O-3
Basal cell carcinoma, NOS, of skin of other and unspecified parts of face
+∞
6.3
6
*
8000/3-C55.9
ICD-O-3
Neoplasm, malignant of uterus, NOS
+∞
6.3
6
*
YL1BD
NOMESCO Finland
Extensive CT examination of pelvis for dose design of radiotherapy
+∞
6.3
6
*
WF004
NOMESCO Finland
Palliative radiotherapy
+∞
6.3
6
*
A04AA55
ATC
palonosetron, combinations; systemic
+∞
6.3
6
*
YX9AD
NOMESCO Finland
Other CT eamination for dose design of radiotherapy
+∞
6.3
6
*

LabWAS

↥
OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
22
14
17.71
14.35
1.8
1.3
—
—
—
0
0
75
345
3.02
11.44
2.2
1.6
—
—
—
0
0
13
9
15.45
8.34
1.1
1.0
—
—
—
0
0
65
344
2.40
6.89
2.4
2.0
—
—
—
0
0
15
23
7.01
6.49
1.3
1.3
167.54
76.02
pmol/l
0.52
15
23
99
647
2.19
6.15
9.1
4.8
4.67
4.40
e9/l
0.23
84
547
53
280
2.27
5.48
9.6
3.8
—
—
—
0
0
91
601
2.05
5.23
5.5
3.1
33.40
34.78
g/l
1.67
83
546
42
217
2.22
4.51
2.7
3.0
4.38
5.91
e6/l
0.43
25
107
66
411
1.96
4.29
3.7
3.2
41.37
45.03
e6/l
0.06
48
304
73
479
1.88
4.01
4.6
3.9
153.20
172.42
e6/l
0.12
52
325
57
345
1.96
3.98
4.6
3.7
—
—
—
0
0
18
67
2.88
3.79
1.2
1.1
—
—
—
0
0
57
360
1.86
3.44
3.3
3.1
—
—
—
0
0
79
559
1.74
3.23
4.8
4.7
21.94
26.63
%
2.50
70
507
78
550
1.74
3.22
4.8
4.8
8.51
8.45
%
0.05
69
498
78
553
1.73
3.14
4.4
4.5
62.68
58.62
%
1.82
68
500
77
548
1.71
3.04
4.7
4.5
2.30
2.80
%
1.27
67
494
32
173
2.03
3.02
3.5
2.1
20.21
21.06
%
0.13
26
143
85
624
1.69
2.97
6.0
4.1
1.22
1.22
mmol/l
0.06
77
552
22
103
2.30
2.95
5.3
3.6
—
—
—
0
0
83
607
1.69
2.94
4.7
4.4
0.17
0.19
e9/l
0.43
69
515
70
490
1.70
2.91
3.8
2.0
2.37
2.37
mmol/l
0.01
59
408
74
526
1.69
2.90
4.9
4.5
0.70
0.70
%
0.01
64
469
5
6
8.52
2.76
2.4
3.3
—
—
—
0
0
56
376
1.71
2.68
3.3
3.1
0.14
0.60
e6/l
3.51
40
279
92
703
1.64
2.67
6.7
4.6
1.22
1.23
mmol/l
0.04
80
605
89
676
1.63
2.64
11.5
17.1
1.42
1.35
inr
0.18
22
184
16
69
2.45
2.57
1.3
1.6
—
—
—
0
0
12
46
2.72
2.41
1.3
1.2
—
—
—
0
0
116
954
1.61
2.38
7.7
4.6
80.91
78.00
u/l
0.48
109
858
78
588
1.58
2.30
4.8
4.4
0.60
0.59
e9/l
0.07
65
492
78
591
1.57
2.24
4.8
4.3
0.04
0.04
e9/l
0.21
65
490
16
74
2.28
2.22
3.9
4.1
95.36
94.26
%
0.74
16
74
15
68
2.32
2.18
4.3
2.9
0.74
0.20
e6/l
1.02
15
63
79
604
1.55
2.16
4.8
4.4
3.53
1.80
e9/l
0.41
66
516
23
125
1.96
2.15
2.1
2.0
23.89
27.97
u/l
0.65
18
100
78
602
1.52
2.01
4.3
3.9
—
—
—
0
0
13
59
2.30
1.89
1.4
1.3
—
—
—
0
0
38
253
1.64
1.83
1.5
1.2
—
—
—
0
0
24
141
1.81
1.79
1.7
1.4
—
—
—
0
0
57
422
1.51
1.75
4.8
2.9
7.39
7.40
ph
—
9
63
13
62
2.18
1.70
6.2
5.6
—
—
—
0
0
68
525
1.48
1.69
5.3
5.0
—
—
—
0
0
45
323
1.53
1.58
4.0
2.4
2.53
2.47
mmol/l
2.19
38
276
42
297
1.54
1.58
4.3
3.0
452.42
500.91
mosm/kgh2o
0.77
33
247
93
771
1.43
1.56
4.6
3.6
6.86
6.81
mmol/l
0.09
88
704
7
27
2.66
1.53
2.9
1.3
—
—
—
0
0
13
65
2.08
1.53
1.5
1.3
—
—
—
0
0
23
143
1.70
1.44
4.3
2.6
1.41
2.92
mmol/l
0.62
18
124
15
82
1.91
1.40
1.5
1.3
—
—
—
0
0
40
289
1.49
1.36
3.5
2.5
6.17
7.48
e6/l
0.47
33
255
22
140
1.65
1.27
1.7
1.9
—
—
—
0
0
26
173
1.59
1.27
2.0
1.8
—
—
—
0
0
8
37
2.22
1.23
3.3
4.0
—
—
—
0
0
22
145
1.59
1.12
4.1
2.6
—
—
—
0
0
25
170
1.55
1.12
1.5
1.2
—
—
—
0
0
64
523
1.35
1.08
9.9
7.8
0.00
0.00
e9/l
0.44
53
414
7
35
2.04
1.01
1.1
1.2
—
—
—
0
0
7
36
1.98
0.98
1.0
1.2
—
—
—
0
0
43
339
1.35
0.91
4.3
4.4
—
—
—
0
0
76
651
1.29
0.90
2.2
2.2
88.32
94.93
pmol/l
0.60
42
287
46
371
1.32
0.84
2.2
2.4
2.33
3.35
mg/l
3.79
37
307
15
100
1.55
0.75
6.4
4.6
24.55
24.87
mmol/l
0.14
15
92
5
25
2.03
0.73
1.6
1.2
—
—
—
0
0
26
196
1.38
0.73
1.7
1.2
2.37
2.48
g/l
0.09
11
102
31
241
1.35
0.72
1.2
1.3
0.86
0.94
u/ml
—
7
59
35
280
1.31
0.68
1.6
1.7
2.94
1.42
mg/l
0.52
28
213
11
70
1.61
0.67
3.5
3.5
25.47
25.87
mmol/l
0.09
11
70
22
164
1.39
0.66
1.6
2.3
1.87
1.75
%
0.34
16
145
5
29
1.74
0.64
1.0
1.1
—
—
—
0
0
13
88
1.51
0.62
3.1
3.8
—
—
—
0
0
15
105
1.47
0.62
1.1
1.2
—
—
—
0
0
5
30
1.69
0.62
2.2
3.4
6.92
7.95
kpa
—
5
30
0
21
0.00
0.60
0.0
1.2
—
198.44
—
0
9
135
1273
1.25
0.59
21.2
14.7
37.43
22.01
mg/l
3.64
118
990
0
23
0.00
0.58
0.0
1.8
—
—
—
0
0
12
81
1.52
0.58
1.0
1.2
—
—
—
0
0
15
107
1.44
0.57
2.7
2.6
1.24
1.23
mmol/l
0.06
15
90
8
55
1.48
0.57
1.1
1.2
—
—
—
0
0
61
534
1.22
0.56
3.4
2.7
250.28
92.38
ug/l
1.64
54
475
45
383
1.23
0.54
1.3
1.6
21.15
22.65
nmol/l
0.22
37
324
6
97
0.61
0.53
4.3
3.2
—
—
—
0
0
34
281
1.26
0.53
2.3
2.2
24244.62
12200.40
umol/l
0.20
26
235
47
404
1.22
0.52
4.3
4.3
—
—
—
0
0
13
93
1.43
0.49
2.5
2.6
—
—
—
0
0
103
957
1.18
0.48
6.3
5.1
—
—
—
0
0
7
50
1.42
0.45
1.6
1.1
—
—
—
0
0
8
56
1.45
0.43
3.6
3.6
—
—
—
0
0
98
1046
0.86
0.42
4.4
4.1
15.39
15.09
pmol/l
0.57
86
934
5
34
1.48
0.40
3.6
2.0
—
—
—
0
0
103
965
1.16
0.40
4.2
4.3
20.97
14.93
mm/h
2.62
91
865
19
151
1.29
0.40
1.2
1.3
234.29
684.65
titre
—
7
43
15
118
1.30
0.35
4.0
3.6
—
—
—
0
0
41
362
1.17
0.34
2.0
1.8
1112.45
1218.59
nmol/l
0.36
29
267
6
45
1.34
0.34
3.5
3.2
7.90
7.38
mmol/l
—
6
45
17
208
0.80
0.33
1.5
1.4
112.54
40.34
iu/ml
—
7
77
16
128
1.27
0.33
1.4
1.6
138.68
153.43
ug/g
0.06
11
97
18
148
1.24
0.30
1.8
2.4
2.77
3.66
ug/l
0.64
13
128
16
130
1.25
0.30
4.6
2.6
138.50
84.77
ng/l
—
10
108
65
605
1.12
0.26
4.5
4.1
28.31
91.81
ng/l
0.61
50
442
9
73
1.25
0.26
1.1
1.4
—
—
—
0
0
121
1250
0.90
0.23
4.7
5.3
2.67
2.65
mmol/l
0.09
106
1126
8
103
0.77
0.21
9.6
3.9
—
—
—
0
0
0
11
0.00
0.21
0.0
1.2
—
—
—
0
0
0
11
0.00
0.21
0.0
1.2
—
—
—
0
0
0
10
0.00
0.21
0.0
1.2
—
—
—
0
0
0
10
0.00
0.21
0.0
1.0
—
373.07
—
0
10
0
10
0.00
0.21
0.0
2.8
—
—
—
0
0
0
10
0.00
0.21
0.0
1.0
—
—
—
0
0
0
10
0.00
0.21
0.0
1.0
—
—
—
0
0
0
12
0.00
0.21
0.0
1.3
—
—
—
0
0
0
12
0.00
0.21
0.0
4.6
—
—
—
0
0
17
197
0.85
0.21
1.4
1.3
8.84
11.21
u/ml
—
8
70
6
48
1.26
0.20
3.5
3.1
1.53
1.50
mmol/l
—
6
48
12
99
1.23
0.20
2.2
1.3
—
—
—
0
0
133
1300
1.09
0.16
19.6
14.5
—
—
—
0
0
6
76
0.78
0.16
1.2
1.4
—
—
—
0
0
73
698
1.08
0.16
7.8
6.2
0.00
0.00
estimate
-0.00
12
103
72
689
1.08
0.15
5.8
4.6
0.00
0.00
estimate
-0.00
13
120
137
1342
1.09
0.15
26.7
18.2
3.96
3.97
mmol/l
0.34
132
1296
73
701
1.07
0.14
5.7
4.5
0.00
0.03
estimate
0.50
11
110
14
123
1.15
0.13
2.6
3.4
—
—
—
0
0
33
351
0.93
0.11
3.7
3.6
—
—
—
0
0
37
391
0.93
0.10
3.8
2.8
5.48
5.89
mmol/l
0.39
28
319
40
421
0.94
0.10
4.8
3.4
9.63
4.99
mg/mmol
0.45
24
251
5
46
1.09
0.09
1.0
1.4
—
—
—
0
0
35
368
0.94
0.08
7.4
4.9
0.00
0.00
estimate
-0.00
11
106
37
388
0.94
0.08
3.7
2.9
2804.05
203.01
mg/l
0.72
24
228
5
63
0.79
0.08
1.0
1.1
—
115.26
—
0
18
7
64
1.10
0.08
6.7
5.0
—
—
—
0
0
7
68
1.03
0.08
3.4
1.6
11.26
10.37
g/l
—
7
63
124
1223
1.05
0.07
5.0
5.2
1.88
1.98
mu/l
0.47
109
1107
119
1207
0.96
0.06
4.2
4.6
4.68
4.64
mmol/l
0.14
103
1092
9
103
0.87
0.06
6.6
4.2
—
—
—
0
0
94
923
1.04
0.06
4.4
4.1
—
—
—
0
0
134
1325
1.05
0.06
12.2
8.8
22.21
21.34
u/l
0.21
128
1266
30
312
0.95
0.04
4.9
4.5
50.04
77.39
ng/l
0.50
24
270
134
1330
1.03
0.03
26.0
16.9
80.78
75.16
umol/l
0.86
134
1330
115
1140
1.02
0.02
3.7
4.1
1.31
1.24
mmol/l
0.55
97
1008
36
369
0.97
0.02
6.4
4.2
—
—
—
0
0
34
346
0.98
0.00
1.5
1.7
375.24
485.26
pmol/l
1.91
25
279
118
1186
0.99
0.00
4.1
4.6
1.57
1.59
mmol/l
0.10
100
1070
15
154
0.97
0.00
4.5
3.8
744.13
314.73
ng/l
0.91
15
141
120
1204
0.99
0.00
6.4
6.3
41.57
41.04
mmol/mol
0.23
100
1105
126
1262
0.99
0.00
4.8
4.9
6.13
6.06
mmol/l
0.20
107
1129
138
1377
1.01
0.00
32.0
21.1
264.82
253.96
e9/l
0.84
133
1334
138
1377
1.01
0.00
31.7
21.0
37.55
38.37
%
1.09
131
1247
138
1377
1.01
0.00
32.0
21.1
4.16
4.31
e12/l
3.48
131
1324
138
1377
1.01
0.00
32.0
21.1
8.31
6.74
e9/l
0.93
131
1328
0
6
0.00
0.00
0.0
4.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
7
75
0.93
0.00
1.1
1.4
—
47.47
—
0
6
0
9
0.00
-0.00
0.0
1.1
—
—
—
0
0
7
77
0.91
-0.00
1.0
1.3
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.0
—
—
—
0
0
8
83
0.96
-0.00
2.5
2.1
0.91
1.04
%
—
8
83
0
7
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.9
—
11.96
—
0
9
8
82
0.97
-0.00
2.5
2.1
0.91
0.67
%
—
8
82
0
9
0.00
-0.00
0.0
1.0
—
—
—
0
0
9
91
0.99
-0.00
1.4
1.6
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.4
—
116.55
—
0
8
0
8
0.00
-0.00
0.0
1.1
—
79.13
—
0
8

Mortality – FinRegistry

↥

This endpoint is excluded (different definition than used in FinnGen).

Relationships between endpoints

↥

Index endpoint: C3_UTERUS_NAS_WIDE – Malignant neoplasm of uterus, part unspecified, including Hilmo

GWS hits: -

This endpoint is excluded (different definition than used in FinnGen).